Managed Account Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Managed Account Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$5.52M	Buy	49,643 +1,478	+3%	+$159K	﹤0.01%	1382
2015 Q1	$4.54M	Buy	+48,165	New	+$5.4M	﹤0.01%	1473

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CGT

Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Managed Account Advisors's AGIO Position: Q2 2015 in Review

Managed Account Advisors increased its Agios Pharmaceuticals (AGIO) stake by 3.1% in Q2 2015, buying an estimated $159K and bringing the position to 49,643 shares worth $5.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1382.

Managed Account Advisors first reported a position in AGIO in Q1 2015 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold AGIO as of Q2 2015.

Managed Account Advisors held 49,643 shares of Agios Pharmaceuticals worth $5.52M as of Q2 2015.
Managed Account Advisors bought 1,478 Agios Pharmaceuticals shares in Q2 2015, an estimated $159K.
Agios Pharmaceuticals made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #1382 holding.
Managed Account Advisors first reported a position in Agios Pharmaceuticals in Q1 2015 and has held it in 2 quarters since.
161 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.